Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries
Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries
复制标题
DOI：
10.1016/j.ejphar.2004.02.038
复制
发表时间：
2004-04-05
影响因子：
5
通讯作者：
Kruuse, C
中科院分区：
文献类型：
--
作者：
Birk, S;Edvinsson, L;Kruuse, C
Inhibitors of phosphodiesterases 3 and 4, the main cyclic AMP (cAMP) degrading enzymes in arteries, may have therapeutic potential in cerebrovascular disorders. We analysed the effects of such phosphodiesterases in guinea pig cerebral arteries with organ bath technique and cyclic nucleotide assays. Guinea pig and human cerebral arteries were used for phosphodiesterase assays. Cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone), a phosphodiesterase 3 inhibitor, was compared to conventional phosphodiesterase 3 and 4 inhibitors.Phosphodiesterases 3 and 4 were the major contributors to total cAMP hydrolysis in the arteries examined. The phosphodiesterase 3 inhibitors additionally attenuated cyclic GMP (cGMP) hydrolysis, but relaxant responses were not dependent on an intact endothelium or on the nitric oxide-cGMP pathway. Conversely, the phosphodiesterase 4 inhibitor used was endothelium-dependant and affected by cGMP levels.This suggests that phosphodiesterase 3 inhibitors are still effective under conditions with possible dysfunctional nitric oxide-cGMP pathway, such as in ischemic stroke or cerebral vasospasm. (C) 2004 Elsevier B.V. All rights reserved.
